GPs have key role in shared care of patients with SLE

Practitioner

Volumn 253, Issue 1724, 2009, Pages 19-24

  Amissah Arthur, Maame Boatemaa ^a   Gordon, Caroline ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; GENERAL PRACTICE; HUMAN; KIDNEY DISEASE; MENTAL DISEASE; NEUROLOGIC DISEASE; PROGNOSIS; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS;

FAMILY PRACTICE; HUMANS; KIDNEY DISEASES; LUPUS ERYTHEMATOSUS, CUTANEOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES; PROGNOSIS;

EID: 77649214461     PISSN: 00326518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Isenberg DA. Horsfall A. Systemic lupus erythematosus in adults. In: Oxford Textbook of Rheumatology. pp1145-19. Oxford Medical Publications. Oxford. 1998
2. Urowitz M, Bookman A, Koehler B et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976;60:221-5
3. Tsokos GC, Gordon C, Smolen JS. Systemic Lupus Erythematosus: A Companion to Rheumatology. First Edition. Mosby Elsevier. Philadelphia. 2007
4. Jonsson H, Nived O, Sturfelt G et al. Estimating the incidence of systemic lupus erythematosus in a defined population using multiple sources of retrieval. Br J Rheumatolol 1990; 29(3): 185-8
5. Johnson A, Gordon C, Palmer R et al. The prevalence and incidence of systemic lupus erythematosus in Birmingham, UK, related to ethnicity and country of birth. Arthritis Rheum 1995; 38:551-8
6. Mok CC Lau CS. Pathogenesis of systemic lupus erythematosus. Br Med J 2003; 56(7): 481
7. Patel P. Werth V. Cutaneous lupus erythematosus: a review. Dermatol Clin 2002 ; 203:73-385
8. Wysenbeek A. Guedji D, Amit M et al. Rash in systemic lupus erythematosus: prevalence and relation to cutaneous and non-cutaneous disease manifestations. Ann Rheum Dis 1992; 517:17-19
9. Mosca M, Tani C Aringer M, Bombardieri S et al. EULAR Recommendations for the management of Systemic Lupus Erythematosus (SLE) Report for the Task Force of the European Standing Committee for International Clinical Studies including Therapeutics (ESCISIT). Ann Rheum Dis 2008:67:195-205
10. MacGowan JR, Ellis S, Griffiths M et al. Retrospective analysis of outcome in a cohort of patients with lupus nephritis treated between 1977 and 1999. Rheumatology 2002; 41(9): 981-987
11. Weening JJ. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15(2): 241-250
12. Illei GG, Balow JE Kidney involvement in systemic lupus erythematosus. In: Systemic Lupus Erythematosus: A Companion to Rheumatology, pp 336-350. Mosby Elsevier. Philadelphia. 2007
13. Sivaraj RR, Durrani OM, Denniston AK et al. Ocular manifestations of systemic lupus erythematosus. Rheumatology 2007: 46(12): 1757
14. Hochberg M. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythernatosus. Arthritis and Rheum 1997; 40(9): 1725-34
15. Wallace D. Metzger A, Stecher V et al. Cholesterollowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990; 89:322-6
16. Petri M. Lakatta C Magder L et al. Effect of prednisolone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med. 1994;96:254-9
17. Rahman P, Giadman D. Urowitz M et al. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 1999; 26:325-330
18. Royal College of Ophthalmologists. The British Society of Rheumatology and British Association of Dermatologists. Hydroxychloroquine and Ocular Toxicity: Recommendations on Screening (Replacing the Royal College of Ophthalmologists Guidelines for Screening 2004 and 1998). London. 2009
19. Bohm M, Gaubitz M, Luger T et al. Topical tacrolimus as a therapeutic adjunct in patients with cutaneous lupus erythematosus. Dermatology 2003; 207:381-5
20. Hay E, Gordon C, Emery P. Assessment of lupus: where are we now? Ann Rheum Dis 1993; 52:169-172
21. Griffiths B, Mosca M. Gordon C Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Practice & Research. Clinical Rheumatol 2005; 19(5): 685-708
22. Manzi S. Meilahn EN, Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145(5): 408-415
23. Esdaile JM, Abrahamowicz M, Grodzicky T et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44(10): 2331-2337
24. Bessant R. Hingorani A Patel L et al. Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology 2004; 43(7): 924-929
25. Lima F, Buchanan N. MA Khamashta. Obstetric outcome in systemic lupus erythematosus. Semin Arthritis Rheum 1995; 25:184-192
26. Clowse M, Witter F, Madger L. The impact of increased lupus activity on obsterical outcomes. Arthritis Rheum 2005; 52:514-521